Natasha de Francisco Shapovalova1, Morgane Donadel2, Mark Jit3, Raymond Hutubessy4. 1. Health Systems and Innovation, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland. Electronic address: shapovalovan@who.int. 2. Vaccines, Immunization and Biologicals, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland. Electronic address: morgane.donadel@gmail.com. 3. Modelling and Economics Unit, Public Health England, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Electronic address: mark.jit@lshtm.ac.uk. 4. Vaccines, Immunization and Biologicals, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland. Electronic address: hutubessyr@who.int.
Abstract
OBJECTIVES: The economic burden of seasonal influenza outbreaks as well as influenza pandemics in lower- and middle-income countries (LMIC) has yet to be specifically systematically reviewed. The aim of this systematic review is to assess the evidence of influenza economic burden assessment methods in LMIC and to quantify the economic consequences of influenza disease in these countries, including broader opportunity costs in terms of impaired social progress and economic development. METHODS: We conducted an all language literature search across 5 key databases using an extensive list of key words for the time period 1950-2013. We included studies which explored direct costs (medical and non-medical), indirect costs (productivity losses), and broader economic impact in LMIC associated with different influenza outcomes such as confirmed seasonal influenza infection, influenza-like illnesses, and pandemic influenza. RESULTS: We included 62 full-text studies in English, Spanish, Russian, Chinese languages, mostly from the countries of Latin American and the Caribbean and East Asia and Pacific with pertinent cost data found in 39 papers. Estimates for direct and indirect costs were the highest in Latin American and the Caribbean. Compared to high-income economies, direct costs in LMIC were lower and productivity losses higher. Evidence on broader impact of influenza included impact on the wider national economy, security dimension, medical insurance policy, legal frameworks, distributional impact, and investment flows. CONCLUSION: The economic burden of influenza in LMIC encompasses multiple dimensions such as direct costs to the health service and households, indirect costs due to productivity losses as well as broader detriments to the wider economy. Evidence from sub-Saharan Africa and in pregnant women remains very limited. Heterogeneity of methods used to estimate cost components makes data synthesis challenging. There is a strong need for standardizing research, data collection and evaluation methods for both direct and indirect cost components.
OBJECTIVES: The economic burden of seasonal influenza outbreaks as well as influenza pandemics in lower- and middle-income countries (LMIC) has yet to be specifically systematically reviewed. The aim of this systematic review is to assess the evidence of influenza economic burden assessment methods in LMIC and to quantify the economic consequences of influenza disease in these countries, including broader opportunity costs in terms of impaired social progress and economic development. METHODS: We conducted an all language literature search across 5 key databases using an extensive list of key words for the time period 1950-2013. We included studies which explored direct costs (medical and non-medical), indirect costs (productivity losses), and broader economic impact in LMIC associated with different influenza outcomes such as confirmed seasonal influenza infection, influenza-like illnesses, and pandemic influenza. RESULTS: We included 62 full-text studies in English, Spanish, Russian, Chinese languages, mostly from the countries of Latin American and the Caribbean and East Asia and Pacific with pertinent cost data found in 39 papers. Estimates for direct and indirect costs were the highest in Latin American and the Caribbean. Compared to high-income economies, direct costs in LMIC were lower and productivity losses higher. Evidence on broader impact of influenza included impact on the wider national economy, security dimension, medical insurance policy, legal frameworks, distributional impact, and investment flows. CONCLUSION: The economic burden of influenza in LMIC encompasses multiple dimensions such as direct costs to the health service and households, indirect costs due to productivity losses as well as broader detriments to the wider economy. Evidence from sub-Saharan Africa and in pregnant women remains very limited. Heterogeneity of methods used to estimate cost components makes data synthesis challenging. There is a strong need for standardizing research, data collection and evaluation methods for both direct and indirect cost components.
Authors: David Shapiro; Champica K Bodinayake; Ajith Nagahawatte; Vasantha Devasiri; Ruvini Kurukulasooriya; Jeremy Hsiang; Bradley Nicholson; Aruna Dharshan De Silva; Truls Østbye; Megan E Reller; Christopher W Woods; L Gayani Tillekeratne Journal: Am J Trop Med Hyg Date: 2017-07 Impact factor: 2.345
Authors: Ingeborg M van der Putten; Aggie T G Paulus; Silvia M A A Evers; Raymond C W Hutubessy; Mickael Hiligsmann Journal: Biomed Res Int Date: 2016-12-12 Impact factor: 3.411
Authors: Carl E Koppeschaar; Vittoria Colizza; Caroline Guerrisi; Clément Turbelin; Jim Duggan; W John Edmunds; Charlotte Kjelsø; Ricardo Mexia; Yamir Moreno; Sandro Meloni; Daniela Paolotti; Daniela Perrotta; Edward van Straten; Ana O Franco Journal: JMIR Public Health Surveill Date: 2017-09-19
Authors: Clint Pecenka; Spy Munthali; Paul Chunga; Ann Levin; Win Morgan; Philipp Lambach; Niranjan Bhat; Kathleen M Neuzil; Justin R Ortiz; Raymond Hutubessy Journal: PLoS One Date: 2017-12-27 Impact factor: 3.240
Authors: Vanessa Cozza; Harry Campbell; Howard H Chang; A Danielle Iuliano; John Paget; Neha N Patel; Robert C Reiner; Chris Troeger; Cecile Viboud; Joseph S Bresee; Julia Fitzner Journal: Am J Epidemiol Date: 2021-05-04 Impact factor: 4.897
Authors: Kathleen F Morales; David W Brown; Laure Dumolard; Claudia Steulet; Alba Vilajeliu; Alba Maria Ropero Alvarez; Ann Moen; Martin Friede; Philipp Lambach Journal: Vaccine X Date: 2021-04-20